Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) FCF Margin (2016 - 2025)

Celldex Therapeutics has reported FCF Margin over the past 16 years, most recently at 53901.65% for Q4 2025.

  • Quarterly results put FCF Margin at 53901.65% for Q4 2025, down 5107340.0% from a year ago — trailing twelve months through Dec 2025 was 13820.12% (down 1154523.0% YoY), and the annual figure for FY2025 was 13829.06%, down 1155418.0%.
  • FCF Margin for Q4 2025 was 53901.65% at Celldex Therapeutics, down from 6127.81% in the prior quarter.
  • Over the last five years, FCF Margin for CLDX hit a ceiling of 346.93% in Q2 2021 and a floor of 53901.65% in Q4 2025.
  • Median FCF Margin over the past 5 years was 4454.19% (2021), compared with a mean of 9065.17%.
  • Peak annual rise in FCF Margin hit 1840907bps in 2025, while the deepest fall reached -5107340bps in 2025.
  • Celldex Therapeutics' FCF Margin stood at 4454.19% in 2021, then skyrocketed by 69bps to 1363.73% in 2022, then surged by 41bps to 803.66% in 2023, then plummeted by -252bps to 2828.26% in 2024, then plummeted by -1806bps to 53901.65% in 2025.
  • The last three reported values for FCF Margin were 53901.65% (Q4 2025), 6127.81% (Q2 2025), and 7861.44% (Q1 2025) per Business Quant data.